Cargando…
Case Report: Semaglutide-associated depression: a report of two cases
Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect associated with semaglutide has been reported...
Autores principales: | Li, Jia-Rui, Cao, Jinya, Wei, Jing, Geng, Wenqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495976/ https://www.ncbi.nlm.nih.gov/pubmed/37706035 http://dx.doi.org/10.3389/fpsyt.2023.1238353 |
Ejemplares similares
-
Case report: specific phobia of vaginal penetration in a pregnant patient
por: Geng, Wenqi, et al.
Publicado: (2023) -
Antipsychotics reduces mortality in patients with neuropsychiatric systemic lupus erythematosus: a retrospective study of psychiatric consultation cases
por: Geng, Wenqi, et al.
Publicado: (2023) -
Emotional distress and burnout at a fever clinic in China: Comparison between different periods of COVID-19
por: Geng, Wenqi, et al.
Publicado: (2023) -
Misdiagnosed psychiatric manifestations in a rare disease: a case report of secondary anxiety syndrome in Cushing’s disease
por: Geng, Wenqi, et al.
Publicado: (2023) -
Development and psychometric validation of the hospitalized patients’ expectations for treatment scale-patient version
por: Xiao, Chunfeng, et al.
Publicado: (2023)